JOURNAL OF ANIMAL SCIENCE AND VETERINARY MEDICINE
Integrity Research Journals

ISSN: 2536-7099
Model: Open Access/Peer Reviewed
DOI: 10.31248/JASVM
Start Year: 2016
Email: jasvm@integrityresjournals.org


Four case reports: Effects of fucoidan and fucoxanthin on the treatment of degenerative heart valve disease in dogs

https://doi.org/10.31248/JASVM2020.212   |   Article Number: 1027AB633   |   Vol.5 (4) - August 2020

Received Date: 20 June 2020   |   Accepted Date: 11 August 2020  |   Published Date: 30 August 2020

Authors:  Chih-Hung Tsai# , Hsin-Yuan Chen# and Shih-Min Hsia*

Keywords: Degenerative heart valve disease, echocardiography, fucoidan, fucoxanthin.

Degenerative heart valve disease (DHVD) is the most common heart disease in dogs, especially in small breed dogs weighing less than 20 kg. The incidence in dogs over 13 years old is as high as 85%, and more than 75% of these dogs have mitral valve problems. The valve, which includes the valve leaflet, chordae, and annulus, is mutinously degenerated due to the accumulation of abnormal collagen tissue and glycosaminoglycan, and nodules are formed at the edge of the valve as the disease progresses, eventually resulting in valve insufficiency. To improve the regular treatment of DHVD, especially medication, the natural supplements fucoidan and fucoxanthin were used in this case report. Four small-breed dogs were diagnosed with heart valve disease in the Yukang Veterinary Hospital, and the veterinarian used fucoidan and fucoxanthin as nutritional supplements for the adjuvant treatment of heart valve disease. In the first three cases, it was found that the cardiac function index, including the LA/Ao ratio, significantly improved after 3 to 6 months of continuous administration. Additionally, in the case of American College of Veterinary Internal Medicine (ACVIM) heart grading below Stage B2 after treatment, valve hypertrophy improved, thinned, and flattened, which either reduced the reflux condition caused by valve insufficiency or restored the complete valve closure function. However, in Case 4, the cardiac function index was not improved after 3 to 6 months of continuous administration without the supplement. To the best of our knowledge, this is the first documented clinical study showing that fucoidan and fucoxanthin can improve DHVD in different kinds of dogs.

#These authors contributed equally to this work.

Adams, D. S., Marolf, A. J., Valdés-Martínez, A., Randall, E. K., & Bachand, A. M. (2017). Associations between thoracic radiographic changes and severity of pulmonary arterial hypertension diagnosed in 60 dogs via Doppler echocardiography: A retrospective study. Veterinary radiology & ultrasound: the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association, 58(4), 454-462.
Crossref
 
Alkhatib, B., Freguin-Bouilland, C., Lallemand, F., Henry, J. P., Litzler, P.-Y., Marie, J. P., Richard, V., Thuillez, C., &Plissonnier, D. (2006). Low molecular weight fucan prevents transplant coronaropathy in rat cardiac allograft model. Transplant Immunology, 16(1), 14-19.
Crossref
 
Atkins, C., Bonagura, J., Ettinger, S., Fox, P., Gordon, S., Haggstrom, J., Hamlin, R., Keene, B., Luis-Fuentes, V., &Stepien, R. (2009). Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. Journal of Veterinary Internal Medicine, 23(6), 1142-1150.
Crossref
 
Aupperle, H., &Disatian, S. (2012). Pathology, protein expression and signaling in myxomatous mitral valve degeneration: comparison of dogs and humans. Journal of Veterinary Cardiology: The Official Journal of the European Society of Veterinary Cardiology, 14(1), 59-71.
Crossref
 
Borgarelli, M., & Buchanan, J. W. (2012). Historical review, epidemiology and natural history of degenerative mitral valve disease. Journal of Veterinary Cardiology, 14(1), 93-101.
Crossref
 
Boswood, A., Häggström, J., Gordon, S. G., Wess, G., Stepien, R. L., Oyama, M. A., Keene, B. W., Bonagura, J., MacDonald, K. A., Patteson, M., Smith, S., Fox, P. R., Sanderson, K., Woolley, R., Szatmári, V., Menaut, P., Church, W. M., O'Sullivan, M. L., Jaudon, J. P., Kresken, J. G., Rush, J., Barrett, K. A., Rosenthal, S. L., Saunders, A. B., Ljungvall, I., Deinert, M., Bomassi, E., Estrada, A. H., Fernandez Del Palacio, M. J., Moise, N. S., Abbott, J. A., Fujii, Y., Spier, A., Luethy, M. W., Santilli, R. A., Uechi, M., Tidholm, A., & Watson, P. (2016). Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. Journal of veterinary internal medicine, 30(6), 1765-1779.
Crossref
 
Chang, P. M., Li, K. L., & Lin, Y. C. (2019). Fucoidan-fucoxanthin ameliorated cardiac function via IRS1/GRB2/ SOS1, GSK3β/CREB pathways and metabolic pathways in senescent mice. Mar Drugs, 17(1).
Crossref
 
Dickson, D., Caivano, D., Matos, J. N., Summerfield, N., & Rishniw, M. (2017). Two-dimensional echocardiographic estimates of left atrial function in healthy dogs and dogs with myxomatous mitral valve disease. Journal of Veterinary Cardiology: The Official Journal of the European Society of Veterinary Cardiology, 19(6), 469-479.
Crossref
 
Fox, P. R. (2012). Pathology of myxomatous mitral valve disease in the dog. Journal of Veterinary Cardiology: The Official Journal of the European Society of Veterinary Cardiology, 14(1), 103-126.
Crossref
 
Keene, B. W., Atkins, C. E., Bonagura, J. D., Fox, P. R., Häggström, J., Fuentes, V. L., Oyama, M. A., Rush, J. E., Stepien, R., & Uechi, M. (2019). ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine, 33(3), 1127-1140.
Crossref
 
Lee, C. M., Song, D. W., Ro, W. B., Kang, M. H., & Park, H. M. (2019). Genome-wide association study of degenerative mitral valve disease in Maltese dogs. Journal of Veterinary Science, 20(1), 63-71.
Crossref
 
Li, C., Gao, Y., Xing, Y., Zhu, H., Shen, J., & Tian, J. (2011). Fucoidan, a sulfated polysaccharide from brown algae, against myocardial ischemia-reperfusion injury in rats via regulating the inflammation response. Food and Chemical Toxicology, 49(9), 2090-2095.
Crossref
 
Ljungvall, I., Rishniw, M., Porciello, F., Ferasin, L., & Ohad, D. G. (2014). Murmur intensity in small-breed dogs with myxomatous mitral valve disease reflects disease severity. The Journal of Small Animal Practice, 55(11), 545-550.
Crossref
 
Matsumoto, M., Hosokawa, M., Matsukawa, N., Hagio, M., Shinoki, A., Nishimukai, M., Miyashita, K., Yajima, T., & Hara, H. (2010). Suppressive effects of the marine carotenoids, fucoxanthin and fucoxanthinol on triglyceride absorption in lymph duct-cannulated rats. European Journal of Nutrition, 49(4), 243-249.
Crossref
 
Menciotti, G., Borgarelli, M., Aherne, M., Camacho, P., Häggström, J., Ljungvall, I., Lahmers, S. M., &Abbott, J. A. (2018). Comparison of the mitral valve morphologies of Cavalier King Charles Spaniels and dogs of other breeds using 3D transthoracic echocardiography. Journal of Veterinary Internal Medicine, 32(5), 1564-1569.
Crossref
 
Misbach, C., Pey, P., Gouni, V., Trehiou-Sechi, E., Petit, A. M., Pouchelon, J., &Chetboul, V. (2016). Antemortem diagnosis of a left auricular appendage herniation through a partial pericardial defect in a dog with degenerative mitral valve disease. Schweizer Archiv fur Tierheilkunde, 158(5), 351-356.
Crossref
 
Thomes, P., Rajendran, M., Pasanban, B., & Rengasamy, R. (2010). Cardioprotective activity of Cladosiphon okamuranus fucoidan against isoproterenol induced myocardial infarction in rats. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 18(1), 52-57.
Crossref